Bennett S. Levitan

2.1k citations
84 papers · 1.5k · h-index 22

Impact in

  • Internal Medicine top 5%
    • Venous Thromboembolism Diagnosis and Management
  • Economics and Econometrics top 2%
    • Health Systems, Economic Evaluations, Quality of Life
    • Economic and Environmental Valuation
    • Pharmaceutical Economics and Policy

Papers in

  • Economics and Econometrics 31
    • Health Systems, Economic Evaluations, Quality of Life 28
    • Pharmaceutical Economics and Policy 7
    • Economic and Environmental Valuation 6
  • Pharmacology 13
    • Pharmaceutical industry and healthcare 13
Co-authors
Esther Wilhelmina de Bekker-Grob (15 shared papers)Juhaeri Juhaeri (9 shared papers)Chiara L. Whichello (10 shared papers)Stuart Alan Kauffman (2 shared papers)Jorien Veldwijk (10 shared papers)Brett Hauber (11 shared papers)Eline van Overbeeke (8 shared papers)Isabelle Huys (9 shared papers)
Journals
Patient (11 papers)Value in Health (9 papers)Therapeutic Innovation & Regulatory Science (6 papers)Frontiers in Pharmacology (3 papers)Journal of the American Heart Association (2 papers)
Partner nations
United StatesNetherlandsUnited Kingdom

In The Last Decade

Bennett S. Levitan

82 papers receiving 1.5k citations

Peers

Bennett S. Levitan
Comparison fields: 5 of 121
  • Internal Medicine 108
  • Economics and Econometrics 462
  • General Decision Sciences 26
  • Toxicology 40
  • Pharmacology 96
Replace Amr Makady with:
Amr Makady Netherlands
Jessica A. Myers United States
Hwanhee Hong United States
Mees Mosseveld Netherlands
Diana L. Brixner United States
Maarten J. ten Berg Netherlands
A. John P.M. Overbeke Netherlands
Gregory W. Daniel United States
Jennifer R Martin United States
Laura A. Levit United States
Bennett S. Levitan relative to Amr Makady Netherlands Amr Makady's profile →
Citations per field
00.5×5×10×15×18×
Amr Makady · 1×
Citations per year

Countries citing papers authored by Bennett S. Levitan

Since Specialization
Citations

This map shows the geographic impact of Bennett S. Levitan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bennett S. Levitan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bennett S. Levitan more than expected).

Fields of papers citing papers by Bennett S. Levitan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bennett S. Levitan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bennett S. Levitan. The network helps show where Bennett S. Levitan may publish in the future.

Co-authors

The 25 scholars most cited alongside Bennett S. Levitan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bennett S. Levitan Line = papers co-authored together Bennett S. Levitan links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 84 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review
Drug Discovery Today ·Vikas Soekhai, Chiara L. Whichello, Bennett S. Levitan, Jorien Veldwijk, Cathy Anne Pinto, Bas Donkers, Isabelle Huys, Eline van Overbeeke
2019127
2
A Framework for Incorporating Patient Preferences Regarding Benefits and Risks into Regulatory Assessment of Medical Technologies
Value in Health ·Martin Ho, Anindita Saha, Kimberly McCleary, Bennett S. Levitan, Stephanie A. Christopher, Kristen Zandlo, Ronald Scott Braithwaite, Brett Hauber
2016114
3
Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI’s Patient Groups and Clinical Trials Project
Therapeutic Innovation & Regulatory Science ·Bennett S. Levitan, Kenneth A. Getz, Eric L. Eisenstein, Michelle P. Goldberg, Matthew J. Harker, Sharon E. Hesterlee, Bray Patrick‐Lake, Jamie N. Roberts
2017114
4
Giving Patients’ Preferences a Voice in Medical Treatment Life Cycle: The PREFER Public–Private Project
Patient ·Esther Wilhelmina de Bekker-Grob, Conny Berlin, Bennett S. Levitan, Karim Raza, Kalliopi Christoforidi, Irina Cleemput, Jana Pelouchová, Harald G. Enzmann
201796
5
Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review
Drug Discovery Today ·Eline van Overbeeke, Chiara L. Whichello, Rosanne Janssens, Jorien Veldwijk, Irina Cleemput, Steven Simoens, Juhaeri Juhaeri, Bennett S. Levitan
201874
6
Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study
Frontiers in Pharmacology ·Eline van Overbeeke, Rosanne Janssens, Chiara L. Whichello, Karin Schölin Bywall, Jenny Sharpe, Nikoletta Nikolenko, Berkeley Phillips, Paolo Guiddi
201959
7
Adaptive walks with noisy fitness measurements
Molecular Diversity ·Bennett S. Levitan, Stuart Alan Kauffman
199558
8
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study
Clinical and Applied Thrombosis/Hemostasis ·Alex C. Spyropoulos, Concetta Lipardi, Jianfeng Xu, Wentao Lu, Eunyoung Suh, Žhong Yuan, Bennett S. Levitan, Chiara Sugarmann
201953
9
Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review
BMC Medical Informatics and Decision Making ·Rosanne Janssens, Isabelle Huys, Eline van Overbeeke, Chiara L. Whichello, Sarah Harding, Jürgen Kübler, Juhaeri Juhaeri, Antonio Ciaglia
201944
10
Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions
Clinical Pharmacology & Therapeutics ·Francesco Pignatti, Deborah Ashby, EP Brass, H‐G Eichler, Pascal Frey, HL Hillege, Akiko Hori, Bennett S. Levitan
201536
11
Appraising patient preference methods for decision-making in the medical product lifecycle: an empirical comparison
BMC Medical Informatics and Decision Making ·Chiara L. Whichello, Bennett S. Levitan, Juhaeri Juhaeri, Vaishali K. Patadia, Rachael L. DiSantostefano, Cathy Anne Pinto, Esther Wilhelmina de Bekker-Grob
202034
12
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
Annals of General Psychiatry ·Michael A. Markowitz, Dong‐Jing Fu, Bennett S. Levitan, Srihari Gopal, Ibrahim Turkoz, Larry D Alphs
201331
13
Patient Engagement at a Tipping Point—The Need for Cultural Change Across Patient, Sponsor, and Regulator Stakeholders: Insights From the DIA Conference, “Patient Engagement in Benefit Risk Assessment Throughout the Life Cycle of Medical Products”
Therapeutic Innovation & Regulatory Science ·Meredith Y. Smith, Tarek A. Hammad, Marilyn A. Metcalf, Bennett S. Levitan, Rebecca A. Noel, Anne M. Wolka, Debra L. Michaels, F. Reed Johnson
201631
14
Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA
Patient ·Rosanne Janssens, Selena Russo, Eline van Overbeeke, Chiara L. Whichello, Sarah Harding, Jürgen Kübler, Juhaeri Juhaeri, Karin Schölin Bywall
201929
15
Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty
Vascular Health and Risk Management ·Bennett S. Levitan, Žhong Yuan, Alexander G.G. Turpie, Richard Joel Friedman, Martin Homering, Jesse A. Berlin, Scott D. Berkowitz, Rachel B. Weinstein
201428
16
Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE
CHEST Journal ·Phil Stephen Wells, Martin H. Prins, Bennett S. Levitan, Jan Beyer‐Westendorf, Timothy Brighton, Henri Bounameaux, Alexander T. Cohen, Bruce L. Davidson
201627
17
Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectives
Current Medical Research and Opinion ·Žhong Yuan, Bennett S. Levitan, Paul B.J. Burton, Christine M. Poulos, Brett Hauber, Jesse A. Berlin
201426
18
Patients’ Preferences Related to Benefits, Risks, and Formulations of Schizophrenia Treatment
Psychiatric Services ·Bennett S. Levitan, Michael A. Markowitz, Ateesha Farah Mohamed, F. Reed Johnson, Larry D Alphs, Leslie Citrome, John F. P. Bridges
201526
19
Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force
Value in Health ·Tommi Tervonen, Jorien Veldwijk, Katherine A. Payne, Xinyi Ng, Bennett S. Levitan, Leila G. Lackey, Kevin Marsh, Praveen Thokala
202325
20
Benefit–Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist
Pharmacoepidemiology and Drug Safety ·Christine Radawski, Elaine H. Morrato, Kenneth Hornbuckle, Priya Bahri, Meredith Y. Smith, Juhaeri Juhaeri, Peter G. M. Mol, Bennett S. Levitan
201524

About Bennett S. Levitan

Bennett S. Levitan is a scholar working on Economics and Econometrics, Pharmacology, Internal Medicine, General Health Professions and Cardiology and Cardiovascular Medicine, having authored 84 papers that have together received 1.5k indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (28 papers), Pharmaceutical industry and healthcare (13 papers), Pharmaceutical Economics and Policy (7 papers), Venous Thromboembolism Diagnosis and Management (7 papers), Atrial Fibrillation Management and Outcomes (7 papers), Economic and Environmental Valuation (6 papers), Patient-Provider Communication in Healthcare (6 papers) and Pharmaceutical studies and practices (5 papers). The work is most often cited by research in Internal Medicine (108 citations), Economics and Econometrics (462 citations), General Decision Sciences (26 citations), Toxicology (40 citations) and Pharmacology (96 citations). Bennett S. Levitan has collaborated with scholars based in United States, Netherlands and United Kingdom. Frequent co-authors include Esther Wilhelmina de Bekker-Grob, Juhaeri Juhaeri, Chiara L. Whichello, Stuart Alan Kauffman, Jorien Veldwijk, Brett Hauber, Eline van Overbeeke, Isabelle Huys, Žhong Yuan and Irina Cleemput. Their work appears in journals such as Patient, Value in Health, Therapeutic Innovation & Regulatory Science, Frontiers in Pharmacology and Journal of the American Heart Association.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Amr MakadyBreakdown of academic impact, for papers by Jessica A. MyersBreakdown of academic impact, for papers by Hwanhee HongBreakdown of academic impact, for papers by Mees MosseveldBreakdown of academic impact, for papers by Diana L. BrixnerBreakdown of academic impact, for papers by Maarten J. ten BergBreakdown of academic impact, for papers by A. John P.M. OverbekeBreakdown of academic impact, for papers by Gregory W. DanielBreakdown of academic impact, for papers by Jennifer R MartinBreakdown of academic impact, for papers by Laura A. Levit